Insider Transactions in Q4 2020 at Tff Pharmaceuticals, Inc. (TFFP)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2020
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-90.91%
|
$150,000
$15.24 P/Share
|
|
Dec 23
2020
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+47.62%
|
$20,000
$2.5 P/Share
|
|
Dec 23
2020
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-75.0%
|
$450,000
$15.33 P/Share
|
|
Dec 23
2020
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+42.86%
|
$60,000
$2.5 P/Share
|
|
Dec 11
2020
|
Robert S Mills Director |
SELL
Open market or private sale
|
Direct |
22,794
-58.79%
|
$319,116
$14.58 P/Share
|
|
Dec 11
2020
|
Robert S Mills Director |
BUY
Exercise of conversion of derivative security
|
Direct |
22,794
+37.02%
|
$45,588
$2.5 P/Share
|
|
Dec 07
2020
|
James Brian Windsor Chief Science Officer |
SELL
Open market or private sale
|
Direct |
25,000
-83.33%
|
$375,000
$15.8 P/Share
|
|
Dec 07
2020
|
James Brian Windsor Chief Science Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+45.45%
|
$50,000
$2.5 P/Share
|
|
Dec 04
2020
|
Lung Therapeutics, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,050,000
-9.63%
|
$13,650,000
$13.86 P/Share
|
|
Nov 24
2020
|
Aaron G.L. Fletcher Director |
BUY
Open market or private purchase
|
Direct |
5,000
+4.76%
|
$75,000
$15.13 P/Share
|
|
Nov 13
2020
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$85,000
$17.17 P/Share
|
|
Nov 12
2020
|
Malcolm Fairbairn Director |
SELL
Open market or private sale
|
Indirect |
11,669
-100.0%
|
$175,035
$15.97 P/Share
|
|
Nov 11
2020
|
Randy H Thurman Director |
SELL
Open market or private sale
|
Direct |
34,504
-87.34%
|
$517,560
$15.91 P/Share
|
|
Nov 11
2020
|
Randy H Thurman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,504
+46.62%
|
$69,008
$2.5 P/Share
|
|
Nov 11
2020
|
Malcolm Fairbairn Director |
SELL
Open market or private sale
|
Indirect |
63,331
-84.44%
|
$949,965
$15.93 P/Share
|
|
Nov 11
2020
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
15,722
-100.0%
|
$235,830
$15.76 P/Share
|
|
Nov 11
2020
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,722
+50.0%
|
$31,444
$2.5 P/Share
|
|
Nov 10
2020
|
Glenn R. Mattes President and CEO |
SELL
Open market or private sale
|
Direct |
108,830
-91.58%
|
$1,523,620
$14.99 P/Share
|
|
Nov 10
2020
|
Glenn R. Mattes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,830
+47.8%
|
$217,660
$2.5 P/Share
|
|
Nov 10
2020
|
Kirk Allen Coleman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-93.75%
|
$225,000
$15.12 P/Share
|
|
Nov 10
2020
|
Kirk Allen Coleman Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+48.39%
|
$30,000
$2.5 P/Share
|
|
Nov 10
2020
|
Stephen Rocamboli Director |
SELL
Open market or private sale
|
Direct |
21,278
-100.0%
|
$319,170
$15.14 P/Share
|
|
Nov 10
2020
|
Stephen Rocamboli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
21,278
+50.0%
|
$42,556
$2.5 P/Share
|